Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Tavapadon in Healthy Western and Japanese Subjects
NCT02066909Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tavapadon in Parkinson's disease (PD) (9 cohorts), sponsored by Pfizer. Primary endpoints: Supine and standing vital sign measurements, Amount of unchanged drug excreted in urine relative to dose at Day 28 and 16 more. Started Feb 2014; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02066909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02066909.